CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ...

Fitusiran is a subcutaneously administered small interfering RNA (siRNA) therapy under development for the prophylactic treatment of hemophilia A and B, regardless of the presence of inhibitors.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday ...

Last night, my youngest son, Caeleb, and I talked about our unique experiences with Easter egg hunts. My boy is now a 19-year-old man who is finishing his first year at the University of New Mexico.

While the fourth quarter of 2024 continued the trend seen throughout the year of increasing momentum in FDA new drug approvals, with 16 such approvals handed out, the first quarter of 2025 has ...

Sometimes I hear other women joke about their husbands being their “extra child,” and I can’t help but nod in understanding. Living with Jared, who has severe hemophilia B and a seizure disorder, ...

A fitusiran antithrombin-based dose regimen significantly reduced bleeding rates compared with on-demand clotting factor concentrates and bypassing agents. Fitusiran, an investigational small ...

Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...

has announced the U.S. Food and Drug Administration’s approval of Qfitlia™ (fitusiran), marking it as the first and only treatment designed to lower antithrombin for hemophilia A or B patients ...

Fitusiran is an investigational RNA interference (RNAi) drug in development for haemophilia A and B with or without inhibitors. Alnylam’s RNAi technology uses small interfering RNA molecules to ...